Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in China. The company manufactures and distributes a diverse portfolio including pharmaceutical intermediates and active pharmaceutical ingredients such as 6-APA, 7-ADCA, 7-ACA, D-7ACA, penicillin industrial potassium, amoxicillin, clavulanic acid series, azithromycin, and ceftriaxone sodium; chemical preparations encompassing systemic anti-infectives, cardiovascular medications like nifedipine controlled release tablets, urogenital system drugs and hormones, central nervous system agents, musculoskeletal treatments such as diclofenac sodium sustained-release tablets, digestive tract and metabolism medications, anti-tumor and immunomodulators, blood and hematopoietic system drugs, and respiratory system medications; urine-derived biochemical products; animal vaccines; and general health products including garlic oil soft capsules and lecithin soft capsules. Founded in 1996 by academicians of the Chinese Academy of Engineering and headquartered at No. 378 Jianlu Road, Pudong New District, Shanghai, China, the company listed on the Shanghai Stock Exchange in June 2004 and joined China Pharmaceutical Group Co., Ltd. in April 2010 as a subsidiary, employing approximately 11,472 people and operating within the healthcare sector focused on drug manufacturing for specialty and generic pharmaceuticals. Recent developments include ongoing investments in research and development to expand its pipeline across therapeutic areas such as infectious diseases, cardiovascular conditions, and anti-tumor treatments, alongside maintenance of strategic relationships within the China Pharmaceutical Group ecosystem to support distribution and supply chain efficiency.